Zentiva Past Earnings Performance
Past criteria checks 4/6
Zentiva's earnings have been declining at an average annual rate of -4.5%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 13.1% per year. Zentiva's return on equity is 16.2%, and it has net margins of 20.2%.
Key information
-4.5%
Earnings growth rate
-21.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 13.1% |
| Return on equity | 16.2% |
| Net Margin | 20.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Zentiva S.A. (BVB:SCD) Doing What It Can To Lift Shares
Mar 02
Zentiva's (BVB:SCD) Solid Earnings May Rest On Weak Foundations
May 24Zentiva (BVB:SCD) Has Gifted Shareholders With A Fantastic 201% Total Return On Their Investment
Mar 01Zentiva S.A.'s (BVB:SCD) Stock Is Going Strong: Have Financials A Role To Play?
Jan 25
Zentiva S.A. (BVB:SCD) Investors Are Less Pessimistic Than Expected
Dec 18Revenue & Expenses BreakdownBeta
How Zentiva makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 954 | 193 | 172 | 0 |
| 30 Sep 23 | 906 | 190 | 165 | 0 |
| 30 Jun 23 | 848 | 140 | 158 | 0 |
| 31 Mar 23 | 821 | 137 | 148 | 0 |
| 31 Dec 22 | 760 | 99 | 141 | 0 |
| 30 Sep 22 | 746 | 91 | 131 | 0 |
| 30 Jun 22 | 743 | 103 | 126 | 0 |
| 31 Mar 22 | 717 | 87 | 121 | 0 |
| 31 Dec 21 | 711 | 106 | 115 | 0 |
| 30 Sep 21 | 643 | 61 | 116 | 0 |
| 30 Jun 21 | 607 | 58 | 111 | 0 |
| 31 Mar 21 | 568 | 55 | 106 | 0 |
| 31 Dec 20 | 558 | 66 | 105 | 0 |
| 30 Sep 20 | 572 | 38 | 98 | 0 |
| 30 Jun 20 | 556 | 64 | 97 | 0 |
| 31 Mar 20 | 563 | 45 | 93 | 0 |
| 31 Dec 19 | 559 | 44 | 88 | 0 |
| 30 Sep 19 | 554 | 76 | 85 | 0 |
| 30 Jun 19 | 524 | 248 | 81 | 0 |
| 31 Mar 19 | 504 | 282 | 81 | 0 |
| 31 Dec 18 | 461 | 263 | 80 | 0 |
| 30 Sep 18 | 446 | 269 | 87 | 0 |
| 30 Jun 18 | 452 | 83 | 86 | 0 |
| 31 Mar 18 | 455 | 84 | 85 | 0 |
| 31 Dec 17 | 458 | 90 | 86 | 0 |
| 30 Sep 17 | 449 | 87 | 82 | 0 |
| 30 Jun 17 | 455 | 84 | 78 | 0 |
| 31 Mar 17 | 430 | 71 | 76 | 0 |
| 31 Dec 16 | 420 | 73 | 74 | 0 |
| 30 Sep 16 | 409 | 60 | 70 | 0 |
| 30 Jun 16 | 413 | 61 | 70 | 0 |
| 31 Mar 16 | 407 | 54 | 69 | 0 |
| 31 Dec 15 | 397 | 46 | 67 | 0 |
| 30 Sep 15 | 367 | 50 | 67 | 0 |
| 30 Jun 15 | 372 | 45 | 66 | 0 |
| 31 Mar 15 | 382 | 52 | 70 | 0 |
| 31 Dec 14 | 394 | 55 | 65 | 0 |
| 30 Sep 14 | 364 | 46 | 78 | 0 |
| 30 Jun 14 | 328 | 39 | 74 | 0 |
| 31 Mar 14 | 319 | 41 | 64 | 0 |
| 31 Dec 13 | 290 | 41 | 65 | 0 |
| 30 Sep 13 | 281 | 37 | 71 | 0 |
| 30 Jun 13 | 271 | 39 | 71 | 0 |
Quality Earnings: SCD has high quality earnings.
Growing Profit Margin: SCD's current net profit margins (20.2%) are higher than last year (13.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SCD's earnings have declined by 4.5% per year over the past 5 years.
Accelerating Growth: SCD's earnings growth over the past year (93.7%) exceeds its 5-year average (-4.5% per year).
Earnings vs Industry: SCD earnings growth over the past year (93.7%) exceeded the Pharmaceuticals industry 3.8%.
Return on Equity
High ROE: SCD's Return on Equity (16.2%) is considered low.